Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Intelligent Bio Solutions (NASDAQ: INBS) reported significant growth in its global fingerprint drug testing operations. The company has surpassed 450 active accounts across 24 countries, adding 35 new accounts in fiscal Q3. INBS's Intelligent Fingerprinting Drug Screening System, which delivers results in under 10 minutes through sweat analysis, has expanded into multiple sectors including manufacturing, transport, logistics, engineering, and mining.
Key expansion milestones include entry into Europe's luxury marine sector, regional testing programs in Australia, adoption in Australia's waste and recycling sector, and penetration into Australian retail. The company's distributor network now spans 19 countries through 18 partners. INBS is also planning to introduce a collected testing service and preparing for entry into the U.S. market.
Intelligent Bio Solutions (NASDAQ: INBS) ha registrato una crescita significativa nelle sue operazioni globali di test antidroga tramite impronte digitali. L'azienda ha superato i 450 account attivi in 24 paesi, aggiungendo 35 nuovi account nel terzo trimestre fiscale. Il sistema di screening antidroga Intelligent Fingerprinting di INBS, che fornisce risultati in meno di 10 minuti attraverso l'analisi del sudore, si è ampliato in diversi settori tra cui manifatturiero, trasporti, logistica, ingegneria e estrazione mineraria.
I principali traguardi di espansione includono l'ingresso nel settore nautico di lusso europeo, programmi regionali di test in Australia, adozione nel settore dei rifiuti e riciclaggio australiano e penetrazione nel commercio al dettaglio australiano. La rete di distributori dell'azienda ora copre 19 paesi attraverso 18 partner. INBS sta inoltre pianificando di introdurre un servizio di test raccolti e si sta preparando per entrare nel mercato statunitense.
Intelligent Bio Solutions (NASDAQ: INBS) reportó un crecimiento significativo en sus operaciones globales de pruebas de drogas mediante huellas digitales. La compañía ha superado los 450 cuentas activas en 24 países, añadiendo 35 nuevas cuentas en el tercer trimestre fiscal. El sistema de detección de drogas Intelligent Fingerprinting de INBS, que ofrece resultados en menos de 10 minutos mediante análisis de sudor, se ha expandido a múltiples sectores, incluidos manufactura, transporte, logística, ingeniería y minería.
Los hitos clave de expansión incluyen la entrada en el sector náutico de lujo europeo, programas regionales de pruebas en Australia, adopción en el sector australiano de residuos y reciclaje, y penetración en el comercio minorista australiano. La red de distribuidores de la empresa ahora abarca 19 países a través de 18 socios. INBS también planea introducir un servicio de pruebas recogidas y se está preparando para ingresar al mercado estadounidense.
Intelligent Bio Solutions (NASDAQ: INBS)는 전 세계 지문 약물 검사 사업에서 큰 성장을 보고했습니다. 회사는 24개국에서 450개 이상의 활성 계정을 돌파했으며, 3분기 회계 기간 동안 35개의 신규 계정을 추가했습니다. INBS의 Intelligent Fingerprinting Drug Screening System은 땀 분석을 통해 10분 이내에 결과를 제공하며, 제조업, 운송, 물류, 엔지니어링, 광산업 등 여러 분야로 확장되었습니다.
주요 확장 이정표로는 유럽 고급 해양 부문 진출, 호주 지역 테스트 프로그램, 호주 폐기물 및 재활용 부문 채택, 호주 소매 시장 진출 등이 있습니다. 회사의 유통망은 현재 18개 파트너를 통해 19개국에 걸쳐 있습니다. INBS는 또한 수집 테스트 서비스를 도입할 계획이며 미국 시장 진입을 준비 중입니다.
Intelligent Bio Solutions (NASDAQ : INBS) a annoncé une croissance significative de ses opérations mondiales de tests de dépistage de drogues par empreintes digitales. L'entreprise compte désormais plus de 450 comptes actifs dans 24 pays, ayant ajouté 35 nouveaux comptes au troisième trimestre fiscal. Le système de dépistage Intelligent Fingerprinting d'INBS, qui fournit des résultats en moins de 10 minutes grâce à l'analyse de la sueur, s'est étendu à plusieurs secteurs, notamment la fabrication, le transport, la logistique, l'ingénierie et l'exploitation minière.
Parmi les étapes clés de cette expansion figurent l'entrée dans le secteur nautique de luxe en Europe, des programmes régionaux de tests en Australie, l'adoption dans le secteur australien des déchets et du recyclage, ainsi que la pénétration du commerce de détail australien. Le réseau de distributeurs de l'entreprise couvre désormais 19 pays via 18 partenaires. INBS prévoit également de lancer un service de tests collectés et se prépare à entrer sur le marché américain.
Intelligent Bio Solutions (NASDAQ: INBS) meldete ein erhebliches Wachstum seiner globalen Fingerabdruck-Drogentests. Das Unternehmen hat über 450 aktive Konten in 24 Ländern überschritten und im dritten Geschäftsquartal 35 neue Konten hinzugefügt. Das Intelligent Fingerprinting Drug Screening System von INBS, das Ergebnisse innerhalb von 10 Minuten durch Schweißanalyse liefert, hat sich auf mehrere Branchen ausgeweitet, darunter Fertigung, Transport, Logistik, Ingenieurwesen und Bergbau.
Wichtige Expansionsmeilensteine umfassen den Einstieg in den Luxus-Marine-Sektor Europas, regionale Testprogramme in Australien, die Einführung im australischen Abfall- und Recyclingsektor sowie die Durchdringung des australischen Einzelhandels. Das Vertriebsnetz des Unternehmens erstreckt sich nun über 19 Länder mit 18 Partnern. INBS plant außerdem die Einführung eines gesammelten Testdienstes und bereitet den Eintritt in den US-Markt vor.
- Rapid growth with 450+ active accounts across 24 countries
- 35 new accounts added in fiscal Q3
- Successful expansion into new sectors: luxury marine, waste management, and retail
- Strong global presence with 18 distributors across 19 countries
- Planned entry into the multi-billion-dollar U.S. market
- None.
Insights
INBS shows strong global expansion with 450+ accounts, indicating promising commercial momentum ahead of US market entry.
Intelligent Bio Solutions is executing a classic global expansion playbook with impressive early-stage traction. The company has surpassed 450 active accounts across 24 countries, with 35 new accounts added in fiscal Q3 alone—a significant acquisition rate that demonstrates strengthening product-market fit. The company's fingerprint drug testing technology offers a compelling value proposition through three key differentiators: non-invasive collection, rapid results (under 10 minutes), and superior operational flexibility.
The expansion strategy follows a sophisticated three-pronged approach: 1) deepening penetration in core industrial verticals (manufacturing, transport, logistics, engineering, mining), 2) expanding into adjacent sectors with similar testing requirements (luxury marine, waste management, retail), and 3) building a robust international distribution network spanning 19 countries through 18 partners. This third element is particularly critical as it creates scalable market access without requiring massive direct sales investment.
What's most strategically valuable is how INBS is targeting industries where traditional drug testing methods create operational friction—sectors with distributed workforces, remote operations, or time-sensitive safety requirements. The luxury marine sector in Europe and remote testing programs in Australia provide perfect examples where traditional lab-based testing would be logistically challenging. The planned addition of a collected testing service indicates a move toward a more comprehensive product ecosystem that can address varying customer workflows and volumes. This positions the company for stronger customer retention and potentially higher average revenue per account. The ultimate prize appears to be entry into the U.S. market, which represents a multi-billion-dollar opportunity for workplace drug testing solutions.
Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surges
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical industries.
The Company’s total number of active accounts has surpassed 450, with 35 new accounts added in fiscal Q3 alone. INBS’ Intelligent Fingerprinting Drug Screening System, which detects recent drug use in under ten minutes through fingerprint sweat analysis, continues to gain traction for its speed, portability, and ease of use. This latest growth aligns with INBS’ strategic localization and international expansion plans, targeting high-demand markets.
Recent commercial milestones include:
- Continued growth across core industries – manufacturing, transport, logistics, engineering and mining.
- Expansion into new sectors and global regions:
o Entry into the luxury marine sector in Europe, where remote testing capabilities support yacht-based operations.
o Expansion into regional and remote testing programs in Australia.
o New adoption within Australia’s waste and recycling sector, including pre-employment and for-cause testing.
o Penetration into the retail sector in Australia, including a major e-commerce brand.
- Plans are underway to introduce a collected testing service, providing further flexibility for high-volume customers.
Additionally, INBS is strengthening its distributor ecosystem to support sustained international growth. The Company’s global distributor network now spans 19 countries through 18 partners, enabling localized support and faster market access.
"Traditional testing methods aren’t keeping up with operational demands – our solution is," said Doug Heath, Vice President of Global Sales at Intelligent Bio Solutions. "Industries are moving quickly to adopt a system that’s fast, diverse in its capabilities, and easy to implement."
These latest growth milestones build on the Company’s strategic expansion efforts across high-potential industries and regions. With over 450 active accounts and adoption across 24 countries, INBS continues to scale its global footprint and extend the reach of its fingerprint sweat-based testing system. These commercial developments strengthen the Company’s foundation ahead of its planned entry into the multi-billion-dollar U.S. market.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc/
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
How many active accounts does Intelligent Bio Solutions (INBS) have globally?
What is the Intelligent Fingerprinting Drug Screening System by INBS?
Which industries is INBS expanding into?
How many countries does INBS's distributor network cover?
What are INBS's future expansion plans?
